Commentary - (2024) Volume 8, Issue 4
Immunological Dynamics in Cancer Progression and Therapy
Olivia Stewart*
Department of Cancer Research, National University of Singapore, Singapore
*Correspondence:
Olivia Stewart,
Department of Cancer Research, National University of Singapore,
Singapore,
Email:
Received: 02-Dec-2024, Manuscript No. IPRJO-25-22359;
Editor assigned: 04-Dec-2024, Pre QC No. IPRJO-25-22359 (PQ);
Reviewed: 18-Dec-2024, QC No. IPRJO-25-22359;
Revised: 23-Dec-2024, Manuscript No. IPRJO-25-22359 (R);
Published:
30-Dec-2024, DOI: 10.36648/iprjo-8.4.32
Description
The immunobiology of cancer explores the intricate interplay
between the immune system and tumor cells. Understanding
these interactions is critical for advancing cancer
immunotherapy and improving patient outcomes. This article
delves into the key aspects of cancer immunobiology, including
tumor immunoediting, immune evasion, and therapeutic
implications. Tumor immunoediting is a dynamic process that
encompasses three phases: elimination, equilibrium, and
escape. This concept highlights the dual role of the immune
system in suppressing and promoting tumor progression. In
the initial phase, the immune system identifies and destroys
nascent tumor cells. During this phase, immune surveillance
and tumor cell proliferation reach a balance. Genetic instability
in cancer cells can lead to the emergence of variants that resist
immune attack. Tumor cells develop mechanisms to evade
immune detection and destruction, resulting in uncontrolled
growth and metastasis. Cancer cells employ various strategies
to evade immune responses. Tumors exploit immune
checkpoints, such as PD-1/PD-L1 and CTLA-4, to inhibit T cell
activation and promote immune tolerance. Tumor cells can
downregulate or lose expression of tumor-associated antigens,
making them less recognizable to the immune system. The
tumor microenvironment contains immunosuppressive cells,
such as regulatory T cells, myeloid-derived suppressor cells,
and tumor-associated macrophages. These cells release factors
like TGF-β and IL-10 that inhibit effector T cells. The immune
systemâ??s response to cancer involves both innate and adaptive
components. NK cells, macrophages, and dendritic cells are
crucial for recognizing and eliminating tumor cells. DCs also
bridge the innate and adaptive immune systems by presenting
antigens to T cells. CD8+ T cells are the primary effectors of
anti-tumor immunity, directly killing cancer cells. CD4+ T
helper cells support this response by secreting cytokines that
enhance T cell and macrophage activity. These therapies have
shown remarkable success in cancers like melanoma and nonsmall
cell lung cancer. CAR T cells are genetically engineered
to target specific TAAs, providing a potent and personalized
approach to cancer treatment. Therapeutic cancer vaccines
aim to stimulate the immune system to recognize and attack
tumor cells. Examples include vaccines targeting human
papillomavirus in cervical cancer. These genetically modified
viruses selectively infect and kill cancer cells while stimulating
anti-tumor immunity. The immunobiology of cancer provides
profound insights into the mechanisms of tumor-immune
interactions. By harnessing the immune systemâ??s potential,
researchers and clinicians can develop innovative therapies
to combat cancer more effectively. Despite the success of
immunotherapies, challenges remain. Resistance to ICIs,
limited efficacy in certain cancers, and immune-related adverse
events are significant hurdles. Ongoing research focuses on
overcoming these challenges through combination therapies,
identification of novel immune targets, and personalized
treatment approaches. Continued interdisciplinary efforts will
pave the way for breakthroughs in cancer immunotherapy and
improved patient outcome.
Acknowledgement
None.
Conflict Of Interest
The author's declared that they have no conflict of interest.
Citation: Stewart O (2024) Immunological Dynamics in Cancer Progression and Therapy. Res J Onco. 8:32.
Copyright: © 2024 Stewart O. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.